254
Views
6
CrossRef citations to date
0
Altmetric
Clinical Note

Motion sickness and sopite syndrome associated with parabolic flights: a case report

, &
Pages 189-194 | Received 30 Mar 2015, Accepted 19 Oct 2015, Published online: 01 Dec 2015

References

  • Clément G. & Ngo-Anh J.T. 2013. Space physiology II: Adaptation of the central nervous system to space flight-past, current, and future studies. Eur J Appl Physiol, 113, 1655–1672.
  • Demertzi A., Van Ombergen A., Tomilovskaya E.S., Jeurissen B., Pechenkova E., Di Perri C. et al. 2015. Cortical reorganization in an astronaut’s brain after long-duration spaceflight (in press). Brain Struct. Funct.
  • Gianaros P. & Muth E. 2001. A questionnaire for the assessment of the multiple dimensions of motion sickness. Aviat Space Environ Med 72, 115–119.
  • Golding J.F. 2006. Motion sickness susceptibility. Auton Neurosci Basic Clin, 129, 67–76.
  • Graybiel A. & Knepton J. 1976. Sopite syndrome: a sometimes sole manifestation of motion sickness. Aviat Space Environ Med 47, 873–882.
  • Harm D.L. & Schlegel T.T. 2002. Predicting motion sickness during parabolic flight. Auton Neurosci Basic Clin, 97, 116–121.
  • Hettinger L.J., Berbaum K.S., Kennedy R.S., Dunlap W.P. & Nolan M.D. 1990. Vection and simulator sickness. Mil Psychol, 2, 171–181.
  • Hilbig R., Anken R.H., Bauerle A. & Rahmann H. et al. 2002. Susceptibility to motion sickness in fish: a parabolic aircraft flight study. J Gravit Physiol, 9, 29–30.
  • Johns M.W. 1991. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep, 14, 540–545.
  • Kennedy R., Stanney K., & Lawson B. 1998. Independence of different cybersickness aftereffects: basis for a theory. Aviat Sp Env Med, 43, 181–192.
  • Kennedy R.S., Drexler J., & Kennedy R.C. 2010. Research in visually induced motion sickness. Appl Ergon, 41, 494–503.
  • Kiniorski E.T., Weider SK., Finley J.R., Fitzgerald E.M., Howard JC., Di Nardo P.A. et al. 2004. Sopite symptoms in the optokinetic drum. Aviat Space Environ Med, 75, 872–875.
  • Lackner J.R. 2014. Motion sickness: More than nausea and vomiting. Exp Brain Res, 232, 2493–2510.
  • Lackner J.R. & DiZio P. 2006. Space motion sickness. Exp Brain Res, 175, 377–399.
  • Lawson B.D. & Mead A.M. 1998. The sopite syndrome revisited: Drowsiness and mood changes during real or apparent motion. Acta Astronaut, 43, 181–192.
  • Matsangas P., Johnston J., McCauley M.E. & Miller NL. 2010. Personnel physical activity levels on naval vessels – evidence for soporific and fatigue effects? In Proceedings of the International Conference of Human Performance at Sea (HPAS).
  • Matsangas P. & McCauley M. 2014a. Sopite syndrome: a revised definition. Aviat Space Environ Med , 85, 672–673.
  • Matsangas P. & McCauley M. 2014b. Yawning as a behavioral marker of mild motion sickness and sopite syndrome. . Aviat Space Environ Med, 85, 658–661.
  • Matsangas P., McCauley M., & Becker W. 2014. The effect of mild motion sickness and sopite syndrome on multitasking cognitive performance. Hum. Factors, 75, 872–875.
  • McMaster S.B. & Carney J.M. 1985. Changes in drug sensitivity following acute and chronic exercise. Pharmacol Biochem Behav, 23, 191–194.
  • Miller E.F. & Graybiel A. 1970. A provocative test for grading susceptibility to motion sickness yielding a single numerical score. Acta Otolaryngol Suppl, 274, 1–20.
  • Van Ombergen A., Jeurissen B., Demertzi A., Heine L., Sinitsyn V, Mershina E. et al. 2013. Neuroplasticity in astronauts and patients with vestibular lesions studied with novel MRI methods: proof of concept. In 19th IAA Humans in Space: linking the challanges of space exploration with medicine on Earth. Cologne, Germany.
  • Price N.M., Schmitt L.G., McGuire J., Shaw J.E. & Trobough G. 1981. Transdermal scopolamine in the prevention of motion sickness at sea. Clin Pharmacol Ther, 29, 414–419.
  • Schlegel T.T., Brown T.E., Wood S.J., Benavides E.W., Bondar R.L., Stein F. et al. 2001. Orthostatic intolerance and motion sickness after parabolic flight. J Appl Physiol, 90, 67–82.
  • Schmäl F. 2013. Neuronal mechanisms and the treatment of motion sickness. Pharmacology, 91, 229–241.
  • Simmons R.G., Phillips J.B., Lojewski RA., Wang Z., Boyd J.L., Putcha L. 2010. The efficacy of low-dose intranasal scopolamine for motion sickness. Aviat Space Environ Med, 81, 405–412.
  • Strewe C., Feuerecker M., Nichiporuk I., Kaufmann I., Hauer D., Morukov B. et al. 2012. Effects of parabolic flight and spaceflight on the endocannabinoid system in humans. Rev Neurosci, 23, 673–680.
  • Suri K.B., Crampton G.H., & Daunton N.G. 1979. Motion sickness in cats: A symptom rating scale used in laboratory and flight tests. Aviat Space Environ Med, 50, 614–618.
  • Watson D., Clark L.A. & Tellegen A. 1988. Development and validation of brief measures of positive and negative affect: The PANAS scales. J Pers Soc Psychol, 54, 1063–1070.
  • Weerts A.P., Pattyn N., Putcha L., Hoag S.W., Van Ombergen A., Hallgren E. et al. 2015. Restricted sedation and absence of cognitive impairments after administration of intranasal scopolamine. J Appl Physiol, 119, 213–218.
  • Wood C.D., Manno J.E., Manno BR., Redetzki H.M., Wood M., Vekovius W.A. 1984. Side effects of antimotion sickness drugs. Aviat Space Environ Med, 55, 113–116.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.